Tags: new | drug | curbs | chronic | leukemia | myeloid | chronic

New Drug Alleviates Chronic Leukemia

Monday, 10 Dec 2012 12:13 PM


An experimental leukemia drug from Ariad Pharmaceuticals Inc eliminated the cancer from the bone marrow of nearly half of patients with a chronic form of the disease who had stopped responding to other drugs, according to a 12-month follow-up of a pivotal drug trial.
The trial of the drug, ponatinib, which involved 444 patients, including 267 with chronic myeloid leukemia who had previously been treated with older drugs, also showed that 56 percent of chronic patients achieved the study's goal of a "major response," meaning the disease had nearly disappeared from the bone marrow.
Ariad earlier this year presented interim results from the trial, and U.S. Food and Drug Administration agreed in October to an expedited review. The agency is slated to decide by March 27 whether to approve ponatinib.
"We expect FDA approval sometime in the first quarter," said Tim Clackson, Ariad's chief scientific officer. He said the company is prepared to immediately launch sales of the drug. "We believe the overall trial data suggests activity in all forms of resistant disease."
Ponatinib is designed to target an abnormal tyrosine kinase that is closely associated with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia.
Ariad is also testing the drug in newly diagnosed CML patients. Final results from that trial are expected at the end of 2014, but an interim analysis will occur after half of the trial patients are enrolled, Clackson said.
Around 5,000 U.S. patients are diagnosed with CML each year, and about 2,500 patients will become resistant to their treatment, according to Ariad.




© HealthDay

   
1Like our page
2Share
Health-News
A new drug called ponatinib erased the cancer from the bone marrow of almost half of patients with a form of chronic leukemia who had stopped responding to other drugs.
new,drug,curbs,chronic,leukemia,myeloid,chronic,bone,marrow,ponatinib,abnormal,tyrosine,kinase,chromosome,positive,acute,lymphoblastic,
259
2012-13-10
Monday, 10 Dec 2012 12:13 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved